Menin inhibitors reshape AML care, boosting targeted options for KMT2A- and NPM1-mutant disease, with promising frontline ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic ...
Acute myeloid leukemia (AML) remains one of the most difficult blood cancers to treat. Although drug combinations are often ...
Dr. Gabriel Mannis from Stanford University and Dr. Gail Roboz from Weill Cornell Medicine discussed the evolving treatment ...
Tyrosine kinase inhibitors (TKIs) lead to similar outcomes across racial and ethnic groups when used to treat acute myeloid ...
Stocktwits on MSN
SLS stock pops after-hours as loss shrinks, cash swells — all eyes on high stakes AML trial in 'pivotal' 2026
Net loss in FY25 narrowed to $26.9 million from $30.9 million a year ago, with R&D costs falling to $16 million. ・Phase 3 ...
Hosted on MSN
Acute Myeloid Leukemia Is One of the Most Common Types of Leukemia Among Adults—Look for These Signs
Acute myeloid leukemia (AML) is a type of leukemia, a cancer of the blood and bone marrow. AML specifically affects the myeloid cells, which are immature white blood cells. It is one of the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results